The market expects Quest Diagnostics (DGX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus ...

Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

This was the stock's second consecutive day of gains.

The "Genetic Screening Testing for Reproductive Health Market - A Global and Regional Analysis: Focus on Test Type, Application, Technology, End User, and Country-Level Analysis - Analysis and ...

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

BURNABY, B.C. — LifeLabs union members are urging the B.C. government to review the company’s ownership, one day after ...

GRAIL's groundbreaking Galleri test, detecting 50+ cancers, FDA status, and strategic growth make it a top investment with ...

Following B.C. Premier David Eby’s beefed up made-in-Canada policy announcement on Thursday, a day later, LifeLabs union ...

Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

Barclays analyst Luke Sergott maintained a Hold rating on Quest Diagnostics (DGX – Research Report) today and set a price target of $175.00.

About 1,200 B.C. LifeLabs employees have been on rotating strikes since Feb. 16. On Monday, four of 10 locations in or near ...